Paydirt
JS
Insider

John R Stuelpnagel

Director

John R Stuelpnagel (Director) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in 10x Genomics, Inc. (TXG). The largest single filing was $1.2M of TXG (20,000 sh across 3 lots, as filed), executed Sep 3.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
returns measure stock purchases only
Filings, ttm
2
0 buys · 2 sells
Median delay
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$2.4M
shares × price, as filed
Last traded
Sep 3
Filed Sep 8

Median ADV $190.4M across their filed names

Open performance
Volume by month
$1.2M$618K$0Oct 2024Apr 2025Oct 2025Apr 2026Aug 2026 · sells $1.2MSep 2026 · sells $1.2M
Buys $0 Sells $2.4M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 2 filings

Sector per market data · by filing · past 12 months

Most traded names
TXG 10x Genomics, Inc. TXG · 0 buys · 2 sells 2 filings
Recent filings
TXGSALE 10x Genomics, Inc. View filing → $1.2M
20,000 sh across 3 lots
Exec Sep 3
Filed Sep 8 · 7:00 PM ET
TXGSALE 10x Genomics, Inc. View filing → $1.2M
20,000 sh across 2 lots
Exec Aug 11
Filed Aug 13 · 4:11 PM ET